Cyabra product chief buys stock and warrants

Cyabra Chief Product Officer Yossef Daar increased his stake through a private placement on July 10, 2026.

Rhea-AI Filing Summary

Cyabra Chief Product Officer Yossef Daar increased his stake through a private placement on July 10, 2026. He purchased 53,650 common shares at $0.435 per share from the company and acquired Series A and Series B warrants, each series covering 53,650 shares with exercise prices of $0.45 and $0.50 per share. The warrants become exercisable only after requisite stockholder approval. Following these transactions, Daar directly holds 894,199 common shares and the newly purchased warrants, which expire twelve months and five years, respectively, after their initial exercise dates.

Filing Explained

The common-share purchase is completed, but the warrants create only conditional additional share capacity pending stockholder approval.

The July 13 Form 4 reports that the Chief Product Officer acquired 53,650 common shares in a July 10 private placement and bought warrants covering up to 107,300 additional shares; those warrants are not exercisable until requisite stockholder approval is received.

Under the supplied Form 4 definitions, code A denotes a grant or award and code P denotes an open-market purchase, while the filing's explanation describes the common shares and both warrant purchases as bought from the issuer in the private placement.

The Series B warrants expire 12 months after their initial exercise date, and the Series A warrants expire five years after their initial exercise date, with both periods beginning only after exercise becomes available.

Following the reported transactions, the filing lists 894,199 common shares held directly, plus 53,650 Series B warrants and 107,300 Series A warrants held directly.

Insider Trade Summary

Net Buyer: 107,300 shares

Net Buy 3 txns

Insider Daar Yossef

Role Chief Product Officer

Bought 107,300 shs ($51K)

Type	Security	Shares	Price	Value
Purchase	Common Stock Warrants (right to buy) F2, F3, F4	53,650	$0.45	$24K
Purchase	Common Stock Warrants (right to buy) F5, F6, F7	53,650	$0.50	$27K
Grant/Award	Common Stock F1	53,650	$0.435	$23K

Holdings After Transaction: Common Stock Warrants (right to buy) — 160,950 contracts (Direct); Common Stock — 894,199 shares (Direct)

Footnotes (7)

1. F1. On July 10, 2026, the Reporting Person purchased 53,650 shares of common stock, par value $0.0001 per share (the "Common Stock"), from the Issuer in a private placement transaction (the "Private Placement") at a purchase price of $0.435 per share.
2. F2. The Reporting Person purchased Series B warrants to purchase up to 53,650 shares of Common Stock (the "Series B Warrants") in the Private Placement.
3. F3. The Series B Warrants will become exercisable upon the receipt of the requisite stockholder approval.
4. F4. The Series B Warrants expire twelve (12) months following the initial exercise date.
5. F5. The Reporting Person purchased Series A warrants to purchase up to 53,650 shares of Common Stock (the "Series A Warrants") in the Private Placement.
6. F6. The Series A Warrants will become exercisable upon the receipt of the requisite stockholder approval.
7. F7. The Series A Warrants expire five (5) years following the initial exercise date.

Key Figures

Common stock purchased: 53,650 shares Common stock purchase price: $0.435 per share Series A warrant exercise price: $0.45 per share +3 more

6 metrics

Common stock purchased 53,650 shares Bought from Cyabra in a private placement on July 10, 2026

Common stock purchase price $0.435 per share Price paid for 53,650 common shares in the private placement

Series A warrant exercise price $0.45 per share Series A warrants to purchase up to 53,650 shares of Common Stock

Series B warrant exercise price $0.50 per share Series B warrants to purchase up to 53,650 shares of Common Stock

Shares held after transaction 894,199 shares Direct Cyabra common stock holdings following July 10, 2026 activity

Warrants held after transaction 107,300 warrants Total Series A and B warrants owned after the reported purchases

Key Terms

Private Placement, Series B Warrants, Series A Warrants, requisite stockholder approval

4 terms

Private Placement financial

"purchased 53,650 shares of common stock ... in a private placement transaction"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

Series B Warrants financial

"purchased Series B warrants to purchase up to 53,650 shares of Common Stock"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

Series A Warrants financial

"purchased Series A warrants to purchase up to 53,650 shares of Common Stock"

Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.

requisite stockholder approval regulatory

"will become exercisable upon the receipt of the requisite stockholder approval"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CYAB's Chief Product Officer report on July 10, 2026?

On July 10, 2026, Cyabra Chief Product Officer Yossef Daar purchased 53,650 common shares at $0.435 each in a private placement and acquired Series A and Series B warrants covering a combined 107,300 shares of common stock.

At what prices did the CYAB insider buy stock and warrants?

Yossef Daar bought 53,650 common shares at $0.435 per share. He also acquired Series A warrants with a $0.45 exercise price and Series B warrants with a $0.50 exercise price, each series covering 53,650 underlying shares.

How many CYAB shares does Yossef Daar hold after these transactions?

Following the reported transactions, Yossef Daar directly holds 894,199 shares of Cyabra common stock. He also owns Series A and Series B warrants that together permit the purchase of up to 107,300 additional common shares, subject to stockholder approval for exercisability.

When do CYAB's Series A and Series B warrants become exercisable and when do they expire?

Both Series A and Series B warrants become exercisable only after Cyabra receives the requisite stockholder approval. The Series B warrants expire twelve months after their initial exercise date, while the Series A warrants expire five years after their initial exercise date.

Was the CYAB insider transaction part of a private placement with the company?

Yes. The disclosure states that Yossef Daar purchased 53,650 common shares and related Series A and Series B warrants directly from Cyabra in a private placement transaction, rather than through open‑market purchases for the stock component.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 05:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daar Yossef

(Last) (First) (Middle)

C/O CYABRA, INC.

13 GERSHON SHATZ

(Street)

TEL AVIV 6997543

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYABRA, INC. [ CYAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Product Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		A		53,650(1)	A	$0.435	894,199	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Warrants (right to buy)(2)	$0.45	07/10/2026		P		53,650		(3)	(4)	Common Stock	53,650	$0.45	53,650	D
Common Stock Warrants (right to buy)(5)	$0.5	07/10/2026		P		53,650		(6)	(7)	Common Stock	53,650	$0.5	107,300	D

Explanation of Responses:

1. On July 10, 2026, the Reporting Person purchased 53,650 shares of common stock, par value $0.0001 per share (the "Common Stock"), from the Issuer in a private placement transaction (the "Private Placement") at a purchase price of $0.435 per share.

2. The Reporting Person purchased Series B warrants to purchase up to 53,650 shares of Common Stock (the "Series B Warrants") in the Private Placement.

3. The Series B Warrants will become exercisable upon the receipt of the requisite stockholder approval.

4. The Series B Warrants expire twelve (12) months following the initial exercise date.

5. The Reporting Person purchased Series A warrants to purchase up to 53,650 shares of Common Stock (the "Series A Warrants") in the Private Placement.

6. The Series A Warrants will become exercisable upon the receipt of the requisite stockholder approval.

7. The Series A Warrants expire five (5) years following the initial exercise date.

	/s/ Yael Sandler, Attorney-in-Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)